Journal of Clinical Densitometry
Volume 9, Issue 3 , Pages 281-286 , July 2006

Monitoring of Dual-Energy X-ray Absorptiometry Measurement in Clinical Practice

Received 30 November 2005 ,Revised 18 March 2006 ,Accepted 18 March 2006.

References 

  1. El Maghraoui A, Koumba BA, Jroundi I, Achemlal L, Bezza A, Tazi MA. Epidemiology of hip fractures in 2002 in Rabat, Morocco. Osteoporos Int. 2005;16:597–602
  2. Bono CM, Einhorn TA. Overview of osteoporosis: pathophysiology and determinants of bone strength. Eur Spine J. 2003;12(Suppl 2):S90–S96
  3. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 2000;27:585–590
  4. Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford). 2002;41:1088–1094
  5. Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitom. 2004;7:359–363
  6. El Maghraoui A. Corticosteroid induced osteoporosis. Press Med. 2004;33:1213–1217
  7. Phillipov G, Seaborn CJ, Phillips PJ. Reproducibility of DXA: potential impact on serial measurements and misclassification of osteoporosis. Osteoporos Int. 2001;12:49–54
  8. Nguyen TV, Sambrook PN, Eisman JA. Sources of variability in bone mineral density measurements: implications for study design and analysis of bone loss. J Bone Miner Res. 1997;12:124–135
  9. Lodder MC, Lems WF, Ader HJ, et al. Reproducibility of bone mineral density measurement in daily practice. Ann Rheum Dis. 2004;63:285–289
  10. Maggio D, McCloskey EV, Camilli L, et al. Short-term reproducibility of proximal femur bone mineral density in the elderly. Calcif Tissue Int. 1998;63:296–299
  11. Ravaud P, Reny JL, Giraudeau B, Porcher R, Dougados M, Roux C. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res. 1999;14:1449–1456
  12. Fuleihan GE, Testa MA, Angell JE, Porrino N, Leboff MS. Reproducibility of DXA absorptiometry: a model for bone loss estimates. J Bone Miner Res. 1995;10:1004–1014
  13. Rozenberg S, Vandromme J, Neve J, et al. Precision and accuracy of in vivo bone mineral measurement in rats using dual-energy X-ray absorptiometry. Osteoporos Int. 1995;5:47–53
  14. Nguyen TV, Eisman JA. Assessment of significant change in BMD: a new approach. J Bone Miner Res. 2000;15:369–372
  15. Gluer CC. Monitoring skeletal changes by radiological techniques. J Bone Miner Res. 1999;14:1952–1962
  16. Bland J, Altman D. Statistical methods for assessing agreement between methods of clinical measurement. Lancet. 1986;i:307–310
  17. El Maghraoui A, Do Santos Zounon AA, Jroundi I, et al. Reproducibility of bone mineral density measurements using dual X-ray absorptiometry in daily clinical practice. Osteoporos Int. 2005;16:1742–1748
  18. Johnson SL, Petkov VI, Williams MI, Via PS, Adler RA. Improving osteoporosis management in patients with fractures. Osteoporos Int. 2005;16:1079–1085
  19. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European foundation for osteoporosis and bone disease. The Scientific Advisory Board and the Board of National Societies. Osteoporos Int. 1996;6:256–261
  20. El Maghraoui A, Borderie D, Edouard R, Roux C, Dougados M. Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J Rheumatol. 1999;26:2205–2209
  21. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int. 2001;12:605–609
  22. El Maghraoui A. Osteoporosis and ankylosing spondyltis. Joint Bone Spine. 2004;71:573–578
  23. Eastell R. Assessment of bone density and bone loss. Osteoporos Int. 1996;6(Suppl):3–5
  24. Glüer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genank HK. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int. 1995;5:262–270
  25. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate end-point. Statist Med. 2001;20:3175–3188
  26. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281–289
  27. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationship between bone mineral density and incident vertebral fracture risk raloxifene therapy. J Bone Miner Res. 2002;17:1–10
  28. Wasnich RD, Miller P. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231–236
  29. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatement with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586–1592
  30. Watts N, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005;20:2097–2104
  31. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthr Rheum. 1999;42:1246–1254
  32. Roux C, Garnero P, Thomas T, Sabatier JP, Orcel P, Audran M, et al. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine. 2005;72:26–31
  33. Blake GM, Fogelman I. Dual energy x-ray absorptiometry and its clinical applications. Semin Musculoskelet Radiol. 2002;6:207–218

PII: S1094-6950(06)00043-6

doi: 10.1016/j.jocd.2006.03.014

Journal of Clinical Densitometry
Volume 9, Issue 3 , Pages 281-286 , July 2006

Article Tools

* Image Usage & Resolution